The document discusses the evolution of pharma marketing through a modular content strategy enhanced by artificial intelligence (AI), enabling efficient content creation while navigating regulatory challenges. This approach involves breaking down content into reusable modules, improving consistency and compliance, and allowing for faster market delivery. The whitepaper highlights the benefits of this strategy, including better audience targeting, reduced reliance on external agencies, and streamlined approval processes.